Nucleix Ltd.

Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, their patients and the healthcare system. Our first product, Bladder EpiCheck®, is CE-marked in Europe for primary and recurrent bladder and upper tract urinary cancer, and FDA 510(k) cleared in the U.S. for bladder cancer recurrence. It is commercially available in both regions. Our global team operates from San Diego, California in the US and Rehovot, Israel.